1. Home
  2. ATCH vs JSPR Comparison

ATCH vs JSPR Comparison

Compare ATCH & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AtlasClear Holdings Inc.

ATCH

AtlasClear Holdings Inc.

HOLD

Current Price

$0.19

Market Cap

28.7M

Sector

N/A

ML Signal

HOLD

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.62

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATCH
JSPR
Founded
2022
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.7M
26.3M
IPO Year
2024
2019

Fundamental Metrics

Financial Performance
Metric
ATCH
JSPR
Price
$0.19
$0.62
Analyst Decision
Strong Buy
Buy
Analyst Count
1
11
Target Price
$1.00
$15.50
AVG Volume (30 Days)
1.1M
316.1K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
19.22
EPS
0.05
N/A
Revenue
N/A
N/A
Revenue This Year
$84.47
N/A
Revenue Next Year
$39.32
N/A
P/E Ratio
$3.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.32
52 Week High
$0.86
$2.69

Technical Indicators

Market Signals
Indicator
ATCH
JSPR
Relative Strength Index (RSI) 55.27 42.71
Support Level $0.19 $0.55
Resistance Level $0.21 $1.01
Average True Range (ATR) 0.01 0.05
MACD 0.00 -0.01
Stochastic Oscillator 73.67 34.50

Price Performance

Historical Comparison
ATCH
JSPR

About ATCH AtlasClear Holdings Inc.

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: